Table 2.
The scheme of CVAD placement.
| Patient no. | Age at insertion (years) | Weight (kg) | Peak historical inhibitor titer (BU/ml) | Pre-CVAD inhibitor titer (BU/ml) | Type of CVAD | Aims | Days in hospital | Replacement therapy | Preop dose (Pd FVIII IU/kg or rFVIIa μg/kg) | Types and dosage of Postop-CVAD | Postop number of doses | Catheter survival (days) | Inhibitor titer at the end follow‐up period | Complications |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute | Extended | ||||||||||||||
| P1 | 2.83 | 17.3 | 11.4 | <0.6 | Port-A-Cath | Prophylaxis | 3 | Pd FVIII | 57.8 IU/kg | Pd VIII 88.2 IU/kg | 5 | 511 | <0.6 | None | None |
| P2 | 10.33 | 42.4 | 2 | <0.6 | Port-A-Cath | Prophylaxis | 3 | Pd FVIII | 51.9 IU/kg | Pd VIII 311.3 IU/kg | 6 | 314 | <0.6 | None | None |
| P3 | 1.42 | 13.1 | 78.1 | <0.6 | Port-A-Cath | Prophylaxis | 3 | Pd FVIII | 61.1 IU/kg | Pd VIII 320.6 IU/kg | 7 | 33 Removal |
2.2 | Restlessness | Infection |
| P4 | 0.83 | 9 | <0.6 | <0.6 | Port-A-Cath | Prophylaxis | 5 | Pd FVIII | 44.4 IU/kg | Pd VIII 577.8 IU/kg | 13 | 279 | <0.6 | Buckling (Revision) |
None |
| P5 | 3.75 | 14.8 | 68 | 0.9 | Port-A-Cath | Prophylaxis | 5 | Pd FVIII | 54.1 IU/kg | Pd VIII 513.5 IU/kg | 10 | 277 | <0.6 | None | None |
| P6 | 6.08 | 20 | 44 | <0.6 | Port-A-Cath | Prophylaxis | 5 | Pd FVIII | 50.0 IU/kg | Pd VIII 400 IU/kg | 8 | 189 | <0.6 | None | None |
| P7 | 0.58 | 12 | <0.6 | <0.6 | Port-A-Cath | Prophylaxis | 3 | Pd FVIII | 50.0 IU/kg | Pd VIII 300 IU/kg | 6 | 69 | <0.6 | Restlessness + fever | None |
| P8 | 3.25 | 14.2 | <0.6 | <0.6 | Port-A-Cath | Prophylaxis | 3 | Pd FVIII | 56.3 IU/kg | Pd VIII 197.2 IU/kg | 7 | 42 | <0.6 | Restlessness | None |
| P9 | 1.50 | 12 | 8.8 | 3.4 | Port-A-Cath | ITI | 3 | rFVIIa + PCC | 83.0 μg/kg | rFVIIa 3mg + PCC 1200IU | 7 | 14 | 3.9 | Haematomas | None |
| P10 | 1.83 | 9.3 | 512 | 45.1 | PICC | ITI + IS | 3 | rFVIIa + PCC | 106.5 μg/kg | rVIIa 5 mg + PCC 600 IU | 7 | 73 | 161.3 | None | Occlusion |
| P11 | 1.75 | 14.1 | 512 | 161.3 | PICC | ITI + IS | 3 | rFVIIa + PCC | 70.9 μg/kg | rVIIa 5 mg + PCC 300 IU | 6 | 80 | 71.9 | None | Rash/Infection |
| P12 | 1.92 | 11.9 | 1024 | 161.3 | PICC | ITI + IS | 2 | rFVIIa | 84.0 μg/kg | rVIIa 5 mg | 5 | 371 | 6.6 | None | Occlusion/Crack |
| P13 | 1.67 | 12.1 | 84.5 | 81.9 | PICC | ITI + IS | 3 | rFVIIa + PCC | 82.6 μg/kg | rVIIa 2 mg + PCC 1800 IU | 5 | 224 | 0.7 | None | Crack |
| P14 | 1.92 | 11 | 25.3 | 10 | PICC | ITI | 2 | rFVIIa + PCC | 90.9 μg/kg | rVIIa 3 mg + PCC 1200 IU | 6 | 229 | ＜0.6 | None | Infection |
| P15 | 2.58 | 14 | 76.8 | 76.8 | PICC | ITI + IS | 3 | rFVIIa + PCC | 142.9 μg/kg | rVIIa 5 mg + PCC 600 IU | 6 | 279 | ＜0.6 | None | Occlusion |
| P16 | 1.25 | 9 | 75.5 | 31 | PICC | ITI + IS | 2 | rFVIIa | 111.1 μg/kg | rVIIa 5 mg | 5 | 340 | 2.6 | None | Occlusion/Crack |
| P17 | 1.06 | 13.1 | 86.4 | 78.1 | PICC | ITI + IS | 2 | rFVIIa | 76.4 μg/kg | rVIIa 5 mg | 5 | 110 | 2.2 | None | Rash/Crack |
CVAD: central venous access devices; PICC: peripherally inserted central catheter; ITI: immune tolerance therapy.